日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Female pulmonologists experienced poorer health and reduced quality of life related to their professional activities

女性肺科医生由于职业活动,健康状况较差,生活质量下降。

Leloup, Claire; Mesa, Emilie; Basille, Damien; Boudoussier, Augustin; Maurac, Arnaud; Grassion, Léo; Rolland-Debord, Camille; Larrouture, Iban; Martin, Clémence; Jeny, Florence; Maitre, Thomas; Patout, Maxime; Sese, Lucile; Soumagne, Thibaud; Gille, Thomas; Justeau, Grégoire; Salvator, Hélène; Messika, Jonathan; Jutant, Etienne-Marie; Bironneau, Vanessa; Le Rouzic, Olivier; Duruisseaux, Michael; Baptista, Bruno Ribeiro; Toffart, Anne-Claire; Valentin, Simon; Zysman, Maéva

COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors

患有非小细胞肺癌的慢性阻塞性肺病患者对PD-(L)1免疫检查点抑制剂的反应更好。

Boudoussier, Augustin; Larrouture, Iban; Henrot, Pauline; Veillon, Rémi; Bardel, Claire; Chautemps, Camille; Caumont, Charline; Schilfarth, Pierre; Duruisseaux, Michael; Zysman, Maeva

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50

更正:真实世界多中心队列研究,评估一线帕博利珠单抗单药或联合铂类化疗治疗PD-L1≥50的非小细胞肺癌的效果

Pons-Tostivint, E; Hulo, P; Guardiolle, V; Bodot, L; Rabeau, A; Porte, M; Hiret, S; Demontrond, P; Curcio, H; Boudoussier, A; Veillon, R; Mayenga, M; Dumenil, C; Chatellier, T; Gourraud, P A; Mazieres, J; Bennouna, J

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50

一项真实世界多中心队列研究,评估帕博利珠单抗单药或联合铂类化疗一线治疗PD-L1≥50的非小细胞肺癌的疗效。

Pons-Tostivint, E; Hulo, P; Guardiolle, V; Bodot, L; Rabeau, A; Porte, M; Hiret, S; Demontrond, P; Curcio, H; Boudoussier, A; Veillon, R; Mayenga, M; Dumenil, C; Chatellier, T; Gourraud, P A; Mazieres, J; Bennouna, J